摘要
目的探讨胃泌素释放肽前体(ProGRP)和血清神经元特异性烯醇化酶(NSE)在小细胞肺癌(SCLC)诊断中的临床应用价值.方法分别采用化学发光微粒子免疫检测法和免疫发光夹心法检测31例SCLC患者和36例非小细胞肺癌(NSCLC)患者血清中的ProGRP和NSE水平,并分析二者对SCLC的诊断价值.结果 SCLC组患者ProGRP、NSE水平均高于NSCLC组患者,差异均有统计学意义(P﹤0.05),且ProGRP诊断SCLC的灵敏度和特异度均高于NSE.结论与NSE比较,血清ProGRP作为诊断SCLC的肿瘤标志物,具有灵敏度、特异度高的特点,在SCLC的诊断中有重要的临床应用价值.
Objective To explore the clinical diagnostic value of pro-gastrin releasing peptide (ProGRP) and serum neuron specific enolase (NSE) in the detection of small cell lung cancer (SCLC). Method ProGRP and NSE levels in the serum of 31 patients with SCLC and 36 patients with non-small cell lung cancer (NSCLC) were measured by chemiluminescent microparticle immunoassay and immunoluminescence sandwich immunoassay, respectively, and their diagnostic value for SCLC were analyzed. Result The levels of ProGRP and NSE in SCLC group were significantly higher than those in NSCLC group, showing statistically significant differences (P<0.05). The sensitivity and specificity of ProGRP in diagnosing SCLC were both higher compared to NSE. Conclusion Serum ProGRP is more sensitive and specific than NSE as a tumor marker in the diagnosis of SCLC, and it is of important clinical value in the diagnosis of SCLC.
作者
单娟
丁涤非
刘林龙
李珊珊
SHAN Juan;DING Difei;LIU Linlong;LI Shanshan(Department of Oncology, PLA 902 Hospital, Bengbu 233012, Anhui, China;Department of Infectious Disease, PLA 902 Hospital, Bengbu 233012, Anhui, China)
出处
《癌症进展》
2019年第14期1694-1696,共3页
Oncology Progress
